Brian Budke

University of Chicago — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

13h-index1.1kcitations35works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

DNA Repair Mechanisms(16), FOXO transcription factor regulation(9), Cancer therapeutics and mechanisms(7), PARP inhibition in cancer therapy(7), DNA and Nucleic Acid Chemistry(4)

Publications35 total

Mei5–Sae3 stabilizes both active and inactive forms of Dmc1 filaments independently of its impact on ATP hydrolysis
Nucleic Acids Research·2025Open Access
Diabetics and Insulin Resistant Patients, Especially Post COVID-19, Have an Increased Biologic Age From Analysis of Brain FDG PET
Metabolism·2024
Supplementary Figure 1 from Maternal Embryonic Leucine Zipper Kinase (MELK), a Potential Therapeutic Target for Neuroblastoma
2023Open Access
Supplementary Figure 3 from Maternal Embryonic Leucine Zipper Kinase (MELK), a Potential Therapeutic Target for Neuroblastoma
2023Open Access
Supplementary Figure 2 from Maternal Embryonic Leucine Zipper Kinase (MELK), a Potential Therapeutic Target for Neuroblastoma
2023Open Access
Data from Maternal Embryonic Leucine Zipper Kinase (MELK), a Potential Therapeutic Target for Neuroblastoma
2023Open Access
Supplementary Figure 3 from Maternal Embryonic Leucine Zipper Kinase (MELK), a Potential Therapeutic Target for Neuroblastoma
2023Open Access
Supplementary Figure 1 from Maternal Embryonic Leucine Zipper Kinase (MELK), a Potential Therapeutic Target for Neuroblastoma
2023Open Access
Supplementary Figure 2 from Maternal Embryonic Leucine Zipper Kinase (MELK), a Potential Therapeutic Target for Neuroblastoma
2023Open Access
Data from Maternal Embryonic Leucine Zipper Kinase (MELK), a Potential Therapeutic Target for Neuroblastoma
2023Open Access
Data from The RAD51-Stimulatory Compound RS-1 Can Exploit the RAD51 Overexpression That Exists in Cancer Cells and Tumors
2023Open Access
Supplementary Materials, Figures 1 - 2, Table 1 from The RAD51-Stimulatory Compound RS-1 Can Exploit the RAD51 Overexpression That Exists in Cancer Cells and Tumors
2023Open Access
Supplementary Materials, Figures 1 - 2, Table 1 from The RAD51-Stimulatory Compound RS-1 Can Exploit the RAD51 Overexpression That Exists in Cancer Cells and Tumors
2023Open Access
Data from The RAD51-Stimulatory Compound RS-1 Can Exploit the RAD51 Overexpression That Exists in Cancer Cells and Tumors
2023Open Access
Noncanonical NF-κB factor p100/p52 regulates homologous recombination and modulates sensitivity to DNA-damaging therapy
Nucleic Acids Research·2022· 8 citedOpen Access
Targeting Non-Canonical NFκB2 to Determine the Effects on Radiation Sensitization
International Journal of Radiation Oncology*Biology*Physics·2021Open Access
Targeting of Non-canonical NF-κB Factor p100/p52 Inhibits Homologous Recombination and Sensitizes Cancer Cells to DNA-damaging Therapy
International Journal of Radiation Oncology*Biology*Physics·2020Open Access
Optimization of Drug Candidates That Inhibit the D‐Loop Activity of RAD51
ChemMedChem·2019· 25 citedOpen Access
Maternal Embryonic Leucine Zipper Kinase (MELK), a Potential Therapeutic Target for Neuroblastoma
Molecular Cancer Therapeutics·2019· 30 citedOpen Access
Abstract PR02: Small molecules that specifically inhibit the D-loop activity of RAD51
Molecular Cancer Research·2017
page 1 of 2Next →

Frequent Co-authors

Philip P. Connell(28), Alan P. Kozikowski(12), Douglas K. Bishop(10), Chanyoung Park(10), Alexandre Chlenski(9), Marija Dobratic(9), Helen R. Salwen(9), Jae-Hyun Park(9), Mark A. Applebaum(9), Susan L. Cohn(9), Ryan S. Miller(8), Emma Wilkinson(8), Hillary L. Logan(7), Ralph R. Weichselbaum(7), Michał Pawłowski(7), Megan Wu(6), Yusuke Nakamura(5), Wei Lv(4), Jennifer M. Mason(4), Yuen‐Ling Chan(3)